Web Analytics

3 Latest Announced Rounds

  • $7,000,000
    Seed

    1 Investors

    Technology, Information and Internet
    Apr 12th, 2024
  • $3,300,000
    Pre-Seed

    7 Investors

    Technology, Information and Internet
    Apr 12th, 2024
  • $3,800,000
    Seed

    4 Investors

    Software Development
    Apr 12th, 2024
$1,933.10M Raised in 90 Funding Rounds in the past 7 Days - View All

Funding Round Profile

oncgnostics GmbH

start up
Germany - Jena, Thüringen
  • 11/09/2023
  • Unknown
  • Undisclosed Amount

oncgnostics develops – based on proprietary epigenetic biomarkers - highly reliable molecular in vitro diagnostic (IVD) tests for screening, follow-up care and therapeutic decisions in cancer diagnostics.


Related People

Martina SchmitzFounder

Martina Schmitz Germany - Jena, Thuringia

oncgnostics develops – based on proprietary epigenetic biomarkers - highly reliable molecular in vitro diagnostic (IVD) tests for screening, follow-up care and therapeutic decisions in cancer diagnostics.
First product is our CE IVD marked test "GynTect", a 2nd-line test for reliably detecting cervical cancer.

A short comic (german) explains what GynTect is doing.

On the Seedmatch-platform, there are a lot of insides on our company (german) and two nice videos about our company.
2016: https://www.seedmatch.de/startups/oncgnostics-2
2017: https://www.seedmatch.de/startups/oncgnostics